Acuitas Investments LLC Boosts Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Acuitas Investments LLC increased its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 8.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 403,280 shares of the medical instruments supplier’s stock after purchasing an additional 31,480 shares during the quarter. AngioDynamics makes up approximately 1.6% of Acuitas Investments LLC’s holdings, making the stock its 19th largest holding. Acuitas Investments LLC’s holdings in AngioDynamics were worth $3,162,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ANGO. Zurcher Kantonalbank Zurich Cantonalbank increased its position in AngioDynamics by 37.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,105 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 2,491 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in AngioDynamics by 11.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,010 shares of the medical instruments supplier’s stock valued at $249,000 after buying an additional 3,442 shares during the period. CTC Alternative Strategies Ltd. purchased a new stake in AngioDynamics in the 3rd quarter valued at about $92,000. Orion Portfolio Solutions LLC grew its holdings in AngioDynamics by 67.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 125,672 shares of the medical instruments supplier’s stock valued at $919,000 after buying an additional 50,639 shares during the period. Finally, Rice Hall James & Associates LLC grew its holdings in AngioDynamics by 53.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 257,752 shares of the medical instruments supplier’s stock valued at $1,884,000 after buying an additional 89,683 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Oppenheimer upgraded AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a report on Friday, April 5th. Raymond James lowered their price target on AngioDynamics from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, January 9th. Finally, HC Wainwright reduced their price objective on AngioDynamics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, January 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, AngioDynamics currently has an average rating of “Moderate Buy” and a consensus target price of $14.25.

AngioDynamics Stock Down 2.7 %

Shares of NASDAQ ANGO traded down $0.16 during midday trading on Wednesday, hitting $5.87. The stock had a trading volume of 586,457 shares, compared to its average volume of 577,346. The company has a market capitalization of $235.15 million, a price-to-earnings ratio of -1.21 and a beta of 0.66. AngioDynamics, Inc. has a 1-year low of $5.26 and a 1-year high of $11.38. The company has a fifty day moving average price of $5.93 and a 200 day moving average price of $6.42.

Insider Activity

In related news, CEO James C. Clemmer purchased 10,000 shares of AngioDynamics stock in a transaction that occurred on Monday, April 8th. The shares were purchased at an average cost of $6.70 per share, with a total value of $67,000.00. Following the transaction, the chief executive officer now owns 539,066 shares of the company’s stock, valued at approximately $3,611,742.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.10% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.